Evaluation of continuous abiraterone acetate (AA) plus prednisone (P) dosing in fasting and fed states in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Chi, K. N. [1 ]
Spratlin, J. [2 ]
Kollmannsberger, C. [1 ]
North, S. [2 ]
Pankras, C. [1 ]
Chien, C. [3 ]
Gonzalez, M. [4 ]
Pang, L. [5 ]
Yu, M. K. [6 ]
Tran, N. P. [6 ]
机构：
[1] BC Canc Agcy, Oncol, Vancouver, BC, Canada
[2] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[3] Janssen Res & Dev, Clin Pharmacol, Titusville, NJ USA
[4] Janssen Res & Dev, Clin Pharmacol, Raritan, NJ USA
[5] Janssen Res & Dev, Biostat Oncol, Raritan, NJ USA
[6] Janssen Res & Dev, WC Clin Oncol, Los Angeles, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2901
引用
收藏
页码：S696 / S697
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Posadas, Edwin M.
    Chit, Kim N.
    de Wit, Ronald
    de Jonge, Maja J. A.
    Attard, Gerhardt
    Friedlander, Terence
    Yu, Margaret
    Hellemans, Peter
    Chien, Caly
    Abrams, Charlene
    Gonzalez, Martha
    Trudel, Geralyn C.
    Chauhan, Vijay
    Saad, Fred
    CANCER RESEARCH, 2015, 75
  • [2] Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Nauseef, Jones T.
    Christos, Paul J.
    Thomas, Charlene
    Nordquist, Luke T.
    Sternberg, Cora N.
    Beltran, Himisha
    Guervil, Sabrina
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    Molina, Ana M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [3] Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Posadas, Edwin M.
    Chi, Kim N.
    De Wit, Ronald
    De Jonge, Maja J.
    Attard, Gerhardt
    Friedlander, Terence W.
    Yu, Margaret K.
    Hellemans, Peter
    Chien, Caly
    Abrams, Charlene Connelly
    Gonzalez, Martha
    Trudel, Geralyn Carol
    Chauhan, Vijay
    Jiao, Juhui James
    Saad, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Molina, Ana
    Christos, Paul
    Hackett, Amy
    Nordquist, Luke
    Gelmann, Edward
    Stein, Mark
    Sternberg, Cora
    Beltran, Himisha
    Gracey, Lauren
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    CANCER RESEARCH, 2019, 79 (13)
  • [5] Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.
    Posadas, Edwin M.
    Chi, Kim N.
    De Wit, Ronald
    De Jonge, Maja J.
    Attard, Gerhardt
    Friedlander, Terence W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [6] Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Nanus, David M.
    Posadas, Edwin M.
    Petrylak, Daniel Peter
    Bruce, Justine Yang
    Lim, Emerson A.
    Peng, Weimin
    Maul, Raymond Scott
    Gonzalez, Martha
    Tran, Namphuong
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [7] Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
    Auchus, Richard J.
    Yu, Margaret K.
    Nguyen, Suzanne
    Mundle, Suneel D.
    ONCOLOGIST, 2014, 19 (12): : 1231 - 1240
  • [8] Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
    A. W. Tolcher
    K. N. Chi
    N. D. Shore
    R. Pili
    A. Molina
    M. Acharya
    T. Kheoh
    J. J. Jiao
    M. Gonzalez
    A. Trinh
    C. Pankras
    N. Tran
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 305 - 313
  • [9] Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
    Tolcher, A. W.
    Chi, K. N.
    Shore, N. D.
    Pili, R.
    Molina, A.
    Acharya, M.
    Kheoh, T.
    Jiao, J. J.
    Gonzalez, M.
    Trinh, A.
    Pankras, C.
    Tran, N.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 305 - 313
  • [10] Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Abida, W.
    Iannotti, N.
    Argon, E. Kocabas
    Appleman, L.
    Michaud, N.
    Rajarethinam, A.
    Adib, D.
    Saltzstein, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S636 - S636
12345